Ocular hypertension
Drug research and approvals for ocular hypertension: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 190 studies of ocular hypertension are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and the EU has 11 authorised medicines for it.
- Recruiting worldwide: 190
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 11
- A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye…NCT07913074 · Phase 2 · Tavo Biotherapeutics · starts Oct 23, 2026
- Effects of Balance Training in Individuals With GlaucomaNCT07910955 · Not applicable · Kanuni Sultan Suleyman Training and Research Hospital · starts Aug 5, 2026
- Anterior Segment Anatomy Assessed by Swept-Source OCT in Ocular Surgery PatientsNCT07903454 · Not reported · Nanfang Hospital, Southern Medical University · starts May 1, 2026
- Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma PatientsNCT07847073 · Phase 4 · Brett King · starts Oct 1, 2026
- iDose TR Administration in an Office-Based Surgery SettingNCT07816692 · Not reported · Glaukos Corporation · starts May 13, 2026
- Magnetic Resonance Imaging of Cerebral Connectivity and Volume in Neurodegeneration and GlaucomaNCT07802769 · Not applicable · University Hospital, Bordeaux · starts Aug 28, 2026
- Effect of Late Ripcord Removal From Glaucoma Drainage DeviceNCT07803536 · Not applicable · Duke University · starts Dec 1, 2026
- A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and DiseasesNCT07780890 · Not reported · Massachusetts General Hospital · starts Aug 18, 2026
- Long-Term Clinical Results of Ab-Interno Trabeculotomy in Glaucoma ManagementNCT07780916 · Not reported · Wuerzburg University Hospital · starts Dec 3, 2025
Approved 13
- TimololBeta-1 adrenergic receptor antagonist
- LatanoprostProstanoid FP receptor agonist
- TravoprostProstanoid FP receptor agonist
- BimatoprostProstanoid FP receptor agonist
- BrinzolamideCarbonic anhydrase II inhibitor
- Latanoprostene bunodProstanoid FP receptor agonist
- DorzolamideCarbonic anhydrase II inhibitor
- BrimonidineAdrenergic receptor alpha-2 agonist
- TafluprostProstanoid FP receptor agonist
- PilocarpineMuscarinic acetylcholine receptor M3 agonist
- BetaxololBeta-1 adrenergic receptor antagonist
- NetarsudilRho-associated protein kinase inhibitor
- Omidenepag isopropylProstanoid EP2 receptor agonist
Phase 3 3
- TrabodenosonAdenosine A1 receptor agonist
- OfloxacinBacterial DNA gyrase inhibitor
- LevobetaxololBeta-1 adrenergic receptor antagonist
Phase 2 5
- DE-104Rho-associated protein kinase inhibitor
- AMA0076Rho-associated protein kinase inhibitor
- VerosudilRho-associated protein kinase inhibitor
- PiclidenosonAdenosine A3 receptor agonist
- AZD-401711-beta-hydroxysteroid dehydrogenase 1 inhibitor
Phase 1 or earlier 5
- TropicamideMuscarinic acetylcholine receptor M3 antagonist
- PhenylephrineAdrenergic receptor alpha-1 agonist
- SAD448Cannabinoid CB1 receptor agonist
- EvodenosonAdenosine A2a receptor agonist
- Bimatoprost grenod
How its trials ended
607 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 135 whose ending is known, 62% met their primary endpoint, 1% missed it and 36% stopped early.
- Completed, result not reported38363%
- Met its primary endpoint8414%
- Status unknown488%
- Ongoing417%
- Stopped: other or unclear325%
- Stopped: enrollment or feasibility61%
- Stopped: sponsor or business decision61%
- Stopped: funding3<1%
- Missed its primary endpoint2<1%
- Stopped: lack of efficacy2<1%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jul 10, 2026 | Clinical trial protocol title: a phase 1/2 study of REGN22530 in participants with primary open angle glaucoma or ocular hypertensionREGN22530 | Regeneron | Ongoing |
| Nov 15, 2023 | CatiolanzeLatanoprost | Santen Oy | EMA ↗ |
| Jan 7, 2021 | RoclandaLatanoprost / netarsudil | Santen Oy | EMA ↗ |
| Nov 19, 2019 | RhokiinsaNetarsudil | Santen Oy | EMA ↗ |
| Jul 18, 2014 | SimbrinzaBrinzolamide; brimonidine tartrate | Novartis Europharm Limited | EMA ↗ |
| Feb 20, 2014 | IzbaTravoprost | Novartis Europharm Limited | EMA ↗ |
| Nov 25, 2008 | AzargaBrinzolamide; timolol | Novartis Europharm Limited | EMA ↗ |
| May 19, 2006 | GanfortBimatoprost; timolol | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Apr 23, 2006 | DuoTravTravoprost; timolol | Novartis Europharm Limited | EMA ↗ |
| Mar 8, 2002 | LumiganBimatoprost | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Nov 27, 2001 | TravatanTravoprost | Novartis Europharm Limited | EMA ↗ |
| Mar 9, 2000 | AzoptBrinzolamide | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA